• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

    31.93 -0.21 (-0.64%)
    Streaming Delayed Price Updated: 12:20 PM EDT, Aug 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Stoke Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗
    This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
    Via Chartmill
    News headline image
    Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    6 Analysts Have This To Say About Stoke Therapeutics ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Examining the Future: Stoke Therapeutics's Earnings Outlook ↗
     
    Via Benzinga
    News headline image
    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗
     
    Via Benzinga
    News headline image
    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.